{"disease":{"id":"early-alzheimer-s-disease","name":"early alzheimer s disease"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06203106","title":"NYSCF Scientific Discovery Biobank","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"New York Stem Cell Foundation Research Institute","has_results":false},{"nct_id":"NCT03887455","title":"A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1906,"lead_sponsor_name":"Eisai Inc.","has_results":false},{"nct_id":"NCT04777396","title":"A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1840,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT04777409","title":"A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1840,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT04468659","title":"AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1400,"lead_sponsor_name":"Eisai Inc.","has_results":false},{"nct_id":"NCT06539169","title":"FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"xCures","has_results":false},{"nct_id":"NCT03507257","title":"Longitudinal Early-onset Alzheimer's Disease Study Protocol","phase":"","overall_status":"RECRUITING","enrollment_count":850,"lead_sponsor_name":"Indiana University","has_results":false},{"nct_id":"NCT07214974","title":"Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Noah Tech, Corp.","has_results":false},{"nct_id":"NCT07033494","title":"A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":340,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT04770220","title":"An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":325,"lead_sponsor_name":"Alzheon Inc.","has_results":true},{"nct_id":"NCT07196592","title":"Development of a Novel Multidimensional Therapeutic Intervention Protocol for MCI","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Yuan Shen","has_results":false},{"nct_id":"NCT04498650","title":"A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":259,"lead_sponsor_name":"Vivoryon Therapeutics N.V.","has_results":false},{"nct_id":"NCT06996730","title":"A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":240,"lead_sponsor_name":"Banner Health","has_results":false},{"nct_id":"NCT07294586","title":"Exploratory Clinical Study and Validation of Blood Biomarkers for Alzheimer's Disease","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Amoneta Diagnostics SAS","has_results":false},{"nct_id":"NCT05122598","title":"Development and Evaluation of Computerized Olfactory Training Program for Cognitive Decline in Early Alzheimer's Disease","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Evon Medics LLC","has_results":false},{"nct_id":"NCT03153371","title":"Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks","phase":"","overall_status":"COMPLETED","enrollment_count":180,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT07252440","title":"A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Shanghai Auzone Biological Technology Co., Ltd.","has_results":false},{"nct_id":"NCT07505095","title":"Efficacy of Lecanemab at Different Therapeutic Doses for Alzheimer's Disease (AD) in Real-World Practice","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":140,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT06868030","title":"Efficacy and Safety of Conventional Symptomatic Drugs Combined with Lencanizumab in the Treatment of Early Alzheimer's Disease: a Multicenter, Prospective, Observational Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"First Hospital of China Medical University","has_results":false},{"nct_id":"NCT04122001","title":"Effects of Electrical Stimulation on Verbal Learning in Typical and Atypical Alzheimer's Disease","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":94,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT04693520","title":"Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"Alzheon Inc.","has_results":false},{"nct_id":"NCT05479552","title":"A Diagnostic Test for Dementia With Lewy Bodies","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":80,"lead_sponsor_name":"CND Life Sciences","has_results":false},{"nct_id":"NCT05655195","title":"Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Massachusetts Institute of Technology","has_results":false},{"nct_id":"NCT07496021","title":"Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"CKD Bio Corporation","has_results":false},{"nct_id":"NCT04599764","title":"High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Early Alzheimer's Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Anhui Medical University","has_results":false},{"nct_id":"NCT06565143","title":"Effect of Transcranial Alternating Current Stimulation(tACS) for Early Alzheimer's Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Anhui Medical University","has_results":false},{"nct_id":"NCT06850597","title":"Efficacy and Safety of Dimethyl Fumarate Among Patients with Mild Cognitive Impairment and Dementia Due to Alzheimer's Disease","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Medical University of Lodz","has_results":false},{"nct_id":"NCT03661034","title":"Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Cognito Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05161715","title":"Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"NewAmsterdam Pharma","has_results":true},{"nct_id":"NCT07512362","title":"Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease.","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":10,"lead_sponsor_name":"Bernard (Barry) Baumel","has_results":false}],"total":30},"guidelines":[],"source":"Drug Landscape verified database"}